← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Melanotan I × Melanotan II × 2 of 4 selected View comparison

Melanotan I

α-MSH analogue

Remove
VS

Melanotan II

Cyclic melanocortin agonist

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target Melanotan IMelanotan II
✓ —
— ✓

Pathway Map

This is a schematic, not a claim that every step shown has been directly demonstrated for each compound. The receptor immediately after each compound is its direct, structurally-confirmed target; anything shown beyond that receptor represents the broader documented signalling axis for that receptor family in general, not a compound-specific downstream finding.

Melanotan I → Predominantly MC1R
Melanotan II → Broader melanocortin receptor agonism

What These Compounds Share

Shared research line

All selected compounds are catalogued under Enhance.

Shared pathway tags
MelanocortinPigmentation
Shared research areas
Pigmentation

Key Differences

Melanotan I MC1R is a direct target of Melanotan I that none of the other selected compounds share. A more MC1R-focused profile than Melanotan II.
Melanotan II MELANOCORTIN is a direct target of Melanotan II that none of the other selected compounds share. Broader melanocortin receptor activity than Melanotan I.

Compound Detail

Melanotan I
What is it?
A lab-made peptide focused specifically on skin pigmentation signalling.
What are people researching/using it for?
Studied for skin tanning and photoprotection.
Other uses being trialed
General pigmentation-disorder research
Worth knowing
"Melanotan-I" is the original research name for [Nle4,D-Phe7]-alpha-MSH -- the same amino acid sequence later developed by Clinuvel into afamelanotide (brand name Scenesse), a slow-release subcutaneous implant. These are the same active peptide, not two related-but-separate molecules; they differ in formulation and delivery method (an immediate peptide vial here vs. a controlled-release implant for the approved drug), not in chemical identity. This confirms the molecule-level identity from the literature -- it does not by itself confirm that any specific Vital Edge batch matches this sequence/purity without its own product-specific lab verification (the same standard applied to TB-500 on this site).

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
An α-MSH analogue with a predominantly MC1R-focused profile, promoting melanogenic signalling.
Synthetic peptide · Synthetic analogue
Primary Targets & Biological System
Melanocortin signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
An analogue of α-MSH that is predominantly selective for MC1R, the melanocortin receptor found mainly on melanocytes (pigment-producing skin cells). Activating MC1R shifts melanocyte pigment production toward eumelanin (the darker pigment) and away from pheomelanin, the basis for its research use in photoprotection and pigmentation studies. This relative MC1R selectivity is what mechanistically distinguishes it from Melanotan II's broader melanocortin-receptor activity.
Research Areas
MelanogenesisPigmentationPhotobiologyMC1R signalling
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
Beta-phase half-life approximately 0.8-1.7 hours (IV/SC)
Measured directly in a 3-participant human PK trial comparing IV, oral and SC administration -- no detectable drug after oral dosing (not orally bioavailable); this is a very small sample.
Research Routes
Subcutaneous (research contexts) (descriptive only — not administration or dosing guidance)
Key Differentiator
A more MC1R-focused profile than Melanotan II.
Considerations
Research Limitations
"Melanotan-I" is the original research name for [Nle4,D-Phe7]-alpha-MSH -- the same amino acid sequence later developed by Clinuvel into afamelanotide (brand name Scenesse), a slow-release subcutaneous implant. These are the same active peptide, not two related-but-separate molecules; they differ in formulation and delivery method (an immediate peptide vial here vs. a controlled-release implant for the approved drug), not in chemical identity. This confirms the molecule-level identity from the literature -- it does not by itself confirm that any specific Vital Edge batch matches this sequence/purity without its own product-specific lab verification (the same standard applied to TB-500 on this site).
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Erythropoietic protoporphyria (EPP)
Afamelanotide (brand name Scenesse) is FDA-approved (since 2019) to increase pain-free light tolerance in EPP, a rare photosensitivity disorder. Afamelanotide is the same [Nle4,D-Phe7]-alpha-MSH sequence historically called Melanotan-I, delivered via a slow-release implant rather than as a standard peptide preparation -- so this is a genuine approved use for this molecule, in that specific approved delivery form. It is not an approval for Melanotan-I as typically sold/administered in research contexts.
Vitiligo
MC1R-pathway agonists have been researched for repigmentation in vitiligo, alongside UV-based therapy. Research on Melanotan I specifically for this purpose is limited.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Melanotan I · A$54.95 A$69.95
Browse products →
View Research Sources (1) →
Skin pigmentation and pharmacokinetics of melanotan-I in humans
Biopharmaceutics & Drug Disposition, 1997 · Human Human · 3 male volunteers · IV, oral and SC compared · PMID 9113347

The paper itself equates "[Nle4-D-Phe7]-alpha-MSH(4-13)" directly with "melanotan-I (MT-I)" -- confirming this is the literature name for the same sequence later marketed as afamelanotide/Scenesse. No detectable drug after oral dosing (not orally bioavailable). SC fully bioavailable vs IV; beta-phase half-life 0.8-1.7h; clearance 0.12-0.19 L/kg/h. Noticeable tanning after IV/SC dosing, peaking at 1 week, still present 3 weeks post-regimen. Very small sample (n=3).

Supports: human_half_life, canonical_name, research_limitations

Melanotan II
What is it?
A lab-made peptide that broadly activates the body's pigmentation and appetite-signalling system.
What are people researching/using it for?
Studied for skin tanning/pigmentation.
Other uses being trialed
Sexual-response researchAppetite-related research
Worth knowing
Not MC1R-selective -- broader melanocortin receptor activity than Melanotan I. Early human trials were small (3-20 participants) and used the compound directly, not the more targeted derivative developed afterward (bremelanotide/PT-141).

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A cyclic α-MSH analogue with broader melanocortin receptor activity than Melanotan I.
Synthetic cyclic α-MSH analogue · Synthetic analogue
Also known as: MT-II
Primary Targets & Biological System
Melanocortin signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A cyclic analogue of α-MSH that activates multiple melanocortin receptors rather than being selective for any single one -- unlike Melanotan I, which is predominantly MC1R-focused. This broader receptor activity is the mechanistic reason Melanotan II's research interest extends beyond pigmentation (MC1R's primary domain) into appetite and sexual-response research, since other melanocortin receptors in the family (such as MC4R) are more strongly linked to those functions.
Research Areas
PigmentationMelanocortin signallingSexual-response researchAppetite/CNS melanocortin biology
Research Profile
Human administration: Limited Preclinical: Available
Pharmacokinetics
Not displayed as a definitive value without a direct source.
Research Routes
Subcutaneous (early human research) (descriptive only — not administration or dosing guidance)
Key Differentiator
Broader melanocortin receptor activity than Melanotan I.
Considerations
Research Limitations
Not MC1R-selective -- broader melanocortin receptor activity than Melanotan I. Early human trials were small (3-20 participants) and used the compound directly, not the more targeted derivative developed afterward (bremelanotide/PT-141).
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Sexual response / erectile function
Two double-blind, placebo-controlled human crossover trials directly tested Melanotan II for this use: in one, 8 of 10 men with psychogenic erectile dysfunction developed clinically apparent erections; in a larger follow-up of 20 men with psychogenic or organic ED, 17 of 20 responded, and increased sexual desire was reported after 68% of Melanotan II doses versus 19% of placebo doses. This is genuine controlled human evidence directly for Melanotan II itself -- it was also the original research basis that led to the development of PT-141/bremelanotide as a more targeted follow-on compound, but Melanotan II has its own directly-studied human trial history, not merely a precursor role.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Melanotan II · A$54.95 A$69.95
Browse products →
View Research Sources (3) →
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study
Journal of Urology, 1998 · Human Human · 10 men with erectile dysfunction of no known organic cause · Not specified in this record -- see prescribing/trial documentation · PMID 9679884

Double-blind, placebo-controlled crossover, RigiScan-monitored over 6 hours. Clinically apparent erections in 8/10 men on Melanotan II. Mean tip-rigidity >80% duration: 38.0 min (MT-II) vs 3.0 min (placebo), P=0.0045.

Supports: experimental_research

Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II
International Journal of Impotence Research, 2000 · Human Human · 20 men with psychogenic or organic erectile dysfunction · PMID 11035391

Double-blind, placebo-controlled crossover, RigiScan-monitored. Erection without sexual stimulation in 17/20 men (mean 41 min tip rigidity >80%). Increased sexual desire reported after 68% of MT-II doses vs 19% of placebo doses (P<0.01). Severe nausea in 12.9% at 0.025 mg/kg.

Supports: experimental_research

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
Life Sciences, 1996 · Human Human · 3 normal male volunteers · Not specified in this record · PMID 8637402

Single-blind, alternating-day, placebo-controlled Phase I safety/pigmentation study. Mild nausea and stretching/yawning correlating with spontaneous erections; increased pigmentation of face/upper body/buttock in 2 of 3 subjects. Recommended future Phase I dose: 0.025 mg/kg/day.

Supports: mechanism_summary, short_description

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.